Clinical trials
Vitreoretinopathy, Proliferative trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 4 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Benha University | 2 |
| Alexandria University | 1 |
| Anggun Rama Yudantha | 1 |
| CHU de Quebec-Universite Laval | 1 |
| Central Hospital, Nancy, France | 1 |
| Federal University of São Paulo | 1 |
| Lahore General Hospital | 1 |
| Mid Atlantic Retina | 1 |
| Peking University People's Hospital | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vitreoretinopathy, Proliferative | 12 |
| Retinal Detachment | 7 |
| Diabetic Retinopathy | 3 |
| Camurati-Engelmann Syndrome | 1 |
| Epiretinal Membrane | 1 |
| Glaucoma | 1 |
| Postoperative Pain | 1 |
| Pterygium | 1 |
| Retinal Perforations | 1 |
Trials
Showing 26 to 12 of 12. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.